Colorectal Adenocarcinoma Clinical Trial
Official title:
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Metastatic Colorectal Cancer：An Observational Cohort Study
This study was an observational cohort study to investigate the efficacy predictors of fuquinitinib combined with anti-PD-1 monoclonal antibody for third-line treatment and above in Chinese patients with advanced colorectal cancer.
Patients with histologically confirmed metastatic or unresectable MSS/MSI-L/pMMR colorectal adenocarcinoma refractory to or intolerant of fluorouracil, oxaliplatin and irinotecan based systemic treatment, were enrolled in the study. All patients will receive a third line therapy with fruquintinib and anti-PD-1 antibody. Clinical and radiographic assessment will be performed regularly. Patients will be treated until disease progression, untolerable toxicity or withdrawal of consent. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04094688 -
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
| Recruiting |
NCT05504252 -
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
|
Phase 2 | |
| Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00597506 -
Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
|
Phase 2 | |
| Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT05477836 -
Feasibility and Safety of MiWEndo-assisted Colonoscopy
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
| Recruiting |
NCT04870879 -
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
|
N/A | |
| Recruiting |
NCT04773769 -
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
|
N/A | |
| Recruiting |
NCT04739072 -
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
|
||
| Recruiting |
NCT06134440 -
ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study
|
N/A | |
| Withdrawn |
NCT03708536 -
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
|
Phase 3 | |
| Withdrawn |
NCT02413853 -
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00165217 -
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04457284 -
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
|
Phase 2 | |
| Suspended |
NCT04111172 -
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06118658 -
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
|
Phase 2 |